Abstract
Purpose
Despite improved treatment options, multiple myeloma (MM) remains an incurable disease. The aim of this study was to investigate the prognostic value of positron emission tomography/computed tomography (PET/CT) using 18F-2’-deoxy-2’-fluorodeoxyglucose ([18F]FDG) in MM patients shortly before and ~100 days after allogeneic hematopoietic cell transplantation (allo-HCT).
Methods
In this retrospective analysis, we evaluated [18F]FDG-PET/CT-scans of 45 heavily pre-treated MM patients before and 27 patients after scheduled allo-HCT. All scans were qualitatively and semi-quantitatively assessed for the presence of active disease. Serological response was recorded according to International Myeloma Working Group (IMWG) criteria. Progression-free (PFS) and overall survival (OS) were correlated with different PET/CT-derived parameters, such as presence, number and maximum standardized uptake value (SUVmax) of focal myeloma lesions. The impact of extramedullary disease on patient outcome was also assessed.
Results
PET/CT negativity -prior to or following allo-HCT- was a favorable prognostic factor for progression-free and overall survival (both, PFS and OS: pre-HSCT p < 0.001, post-HCT p < 0.005). High FDG-uptake (SUVmax > 6.5) revealed a significantly shortened survival compared to patients with a lower SUVmax (<6.5) (OS, 5.0 ± 1.1 m vs. not reached - longest 122.0 m; p < 0.001). Moreover, our data prove that a higher number (>3) of focal lesions (pre-HCT: both PFS and OS: p < 0.001; post-HCT PFS: p < 0.001, OS: p = 0.139) as well as the presence of extramedullary disease serve as adverse prognostic factors prior to and after allo-HCT. At response assessment after allo-HCT, [18F]FDG-PET/CT had a complementary value in prognostication in addition to IMWG criteria alone.
Conclusion
[18F]FDG-PET/CT before and shortly after allogeneic HCT is a powerful predictor for progression-free and overall survival in MM patients.
Similar content being viewed by others
References
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e46.
Bensinger WI, Maloney D, Storb R. Allogeneic hematopoietic cell transplantation for multiple myeloma. Sem Hematol. 2001;38(3):243–9.
Sobh M, Michallet M, Gahrton G, Iacobelli S, van Biezen A, Schonland S, et al. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT chronic malignancies working party. Leukemia. 2016; https://doi.org/10.1038/leu.2016.101.
Hagen PA, Rodriguez TE, Smith S, Tsai S, Al-Mansour Z, Adams W, et al. Timing of allogeneic hematopoietic cell transplantation for high risk multiple myeloma. Biol Blood Marrow Transplant. 2017;23(3):S266.
Oostvogels R, Uniken Venema SM, de Witte M, Raymakers R, Kuball J, Kroger N, et al. In search of the optimal platform for post-allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review. Bone Marrow Transplant. 2017;52(9):1233–40. https://doi.org/10.1038/bmt.2017.141.
Durie BG. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer. 2006;42(11):1539–43. https://doi.org/10.1016/j.ejca.2005.11.037.
Durie BG, Waxman AD, D’Agnolo A, Williams CM. Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med : Off Publ, Soc Nucl Med. 2002;43(11):1457–63.
Regelink JC, Minnema MC, Terpos E, Kamphuis MH, Raijmakers PG, Pieters-van den Bos IC, et al. Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review. Brit J Haematol. 2013;162(1):50–61. https://doi.org/10.1111/bjh.12346.
Bartel TB, Haessler J, Brown TL, Shaughnessy JD Jr, van Rhee F, Anaissie E, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114(10):2068–76. https://doi.org/10.1182/blood-2009-03-213280.
Hillner BE, Siegel BA, Shields AF, Liu D, Gareen IF, Hunt E, et al. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. J Nucl Med : Off Publ Soc Nucl Med. 2008;49(12):1928–35. https://doi.org/10.2967/jnumed.108.056713.
Bredella MA, Steinbach L, Caputo G, Segall G, Hawkins R. Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol. 2005;184(4):1199–204. https://doi.org/10.2214/ajr.184.4.01841199.
van Lammeren-Venema D, Regelink JC. Riphagen, II, Zweegman S, Hoekstra OS, Zijlstra JM. (1)(8)F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review. Cancer. 2012;118(8):1971–81. https://doi.org/10.1002/cncr.26467.
Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118(23):5989–95. https://doi.org/10.1182/blood-2011-06-361386.
Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, et al. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013;121(10):1819–23. https://doi.org/10.1182/blood-2012-08-451690.
Nanni C, Zamagni E, Farsad M, Castellucci P, Tosi P, Cangini D, et al. Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Molec Imaging. 2006;33(5):525–31. https://doi.org/10.1007/s00259-005-0004-3.
Nanni C, Zamagni E, Celli M, Caroli P, Ambrosini V, Tacchetti P, et al. The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients. Clin Nucl Med. 2013;38(2):e74–9. https://doi.org/10.1097/RLU.0b013e318266cee2.
Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467–73. https://doi.org/10.1038/sj.leu.2404284.
Patriarca F, Carobolante F, Zamagni E, Montefusco V, Bruno B, Englaro E, et al. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2015;21(6):1068–73.
Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N et al. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013:blood-2012-08-451690.
Lapa C, Luckerath K, Malzahn U, Samnick S, Einsele H, Buck AK, et al. 18 FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation. Oncotarget. 2014;5(17):7381–91. https://doi.org/10.18632/oncotarget.2290.
Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L, et al. Prospective evaluation of magnetic resonance imaging and [18F]Fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM study. J Clin Oncol. 2017;35(25):2911–8. https://doi.org/10.1200/JCO.2017.72.2975.
Tu H, He Y, Huang T, Choe S, Duan X, Sattar H, et al. Predictive value of 18F-FDG PET/CT scanning in combination with clinical parameters in patients with newly diagnosed multiple myeloma. Eur J Haematol. 2017.
Patriarca F, Einsele H, Spina F, Bruno B, Isola M, Nozzoli C, et al. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability. Biol Blood Marrow Transplant. 2012;18(4):617–26.
Nanni C, Zamagni E, Cavo M, Rubello D, Tacchetti P, Pettinato C, et al. 11 C-choline vs. 18 F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. World J Surg Oncol. 2007;5(1):68.
Cassou-Mounat T, Balogova S, Nataf V, Calzada M, Huchet V, Kerrou K, et al. 18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study. Eur J Nucl Med Mol I. 2016;43(11):1995–2004.
Lin C, Ho C-L, Ng S-H, Wang P-N, Huang Y, Lin Y-C, et al. 11 C-acetate as a new biomarker for PET/CT in patients with multiple myeloma: initial staging and postinduction response assessment. Eur J Nucl Med Mol I. 2014;41(1):41–9.
Fontana F, Ge X, Su X, Hathi D, Xiang J, Cenci S, et al. Evaluating acetate metabolism for imaging and targeting in multiple myeloma. Clin Cancer Res. 2017;23(2):416–29.
Lapa C, Knop S, Schreder M, Rudelius M, Knott M, Jorg G, et al. C-11-methionine-PET in multiple myeloma: correlation with clinical parameters and bone marrow involvement. Theranostics. 2016;6(2):254–61. https://doi.org/10.7150/thno.13921.
Lapa C, Garcia-Velloso MJ, Lückerath K, Samnick S, Schreder M, Otero PR, et al. 11C-methionine-PET in multiple myeloma: a combined study from two different institutions. Theranostics. 2017;7(11):2956.
Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe francophone du Myelome. Blood. 2007;109(8):3489–95.
Avet-Loiseau H, Attal M, Campion L, Caillot D, Hulin C, Marit G, et al. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t (4; 14), del (17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol. 2012;30(16):1949–52.
Dimopoulos MA, Barlogie B, Smith TL, Alexanian R. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med. 1991;115(12):931–5.
Funding
Wilhelm Sander-Stiftung, grant 2013.906.1.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical approval
All procedures involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Disclosure of potential conflict of interest
All authors state that they have nothing to disclose.
Electronic supplementary material
ESM 1
(DOCX 23 kb)
Rights and permissions
About this article
Cite this article
Stolzenburg, A., Lückerath, K., Samnick, S. et al. Prognostic value of [18F]FDG-PET/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantation. Eur J Nucl Med Mol Imaging 45, 1694–1704 (2018). https://doi.org/10.1007/s00259-018-3997-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-018-3997-0